Michael E Prevoznik Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 months ago
Michael E Prevoznik has an estimated net worth of at least $33.9 million*, as of Oct. 29, 2025. They own 38,371 shares of DGX stock. They have sold 175,400 shares of DGX stock since 2021, for an estimated $27.1 million.
Michael E Prevoznik $DGX SEC Form 4 Insider Trading
Michael E Prevoznik has filed a total of 20 insider trades in $DGX since 2021. Their most recent trade was a sale of 1,111 shares, made on Feb 19, 2026. Their largest trade was a sale of 50,604 shares, made on May 17, 2022. We estimate that they now own 38,371 shares of $DGX, worth an estimated $6.8 million.
Insider Trading at $DGX
There have been a total of 124 insider trades reported at $DGX since 2021, with 0 shares purchased and 1.1 million shares sold. The most active insider traders in $DGX stock have been Michael E Prevoznik, Stephen H Rusckowski, and J. E. Davis. The most recent trade was a sale of 958 shares reported by Patrick Plewman (SVP for Diagnostic Services), made on Feb 19, 2026.
History of Insider Stock Trades by Michael E Prevoznik
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
DGX
|
Sale | 1,111 | Feb 19, 2026 | Feb. 20, 2026, 6:12 p.m. |
|
DGX
|
Sale | 144 | Sep 26, 2025 | Sept. 30, 2025, 4:36 p.m. |
|
DGX
|
Sale | 83 | Sep 26, 2025 | Sept. 30, 2025, 4:36 p.m. |
|
DGX
|
Sale | 28,288 | Sep 23, 2025 | Sept. 25, 2025, 4:39 p.m. |
|
DGX
|
Sale | 175 | Sep 24, 2025 | Sept. 25, 2025, 4:39 p.m. |
|
DGX
|
Sale | 4,643 | Mar 17, 2025 | March 19, 2025, 9 p.m. |
|
DGX
|
Sale | 592 | Mar 04, 2025 | March 5, 2025, 5:35 p.m. |
|
DGX
|
Sale | 528 | Feb 27, 2025 | Feb. 28, 2025, 5:38 p.m. |
|
DGX
|
Sale | 604 | Feb 20, 2025 | Feb. 21, 2025, 5:44 p.m. |
|
DGX
|
Sale | 3,009 | Nov 29, 2024 | Dec. 2, 2024, 5:43 p.m. |
|
DGX
|
Sale | 32,137 | Nov 29, 2024 | Dec. 2, 2024, 5:43 p.m. |
|
DGX
|
Sale | 32,551 | Aug 29, 2024 | Sept. 3, 2024, 4:30 p.m. |
|
DGX
|
Sale | 5,611 | Feb 29, 2024 | March 1, 2024, 5:50 p.m. |
|
DGX
|
Sale | 661 | Feb 22, 2024 | Feb. 23, 2024, 5:35 p.m. |
|
DGX
|
Sale | 4,754 | Mar 07, 2023 | March 8, 2023, 5:39 p.m. |
|
DGX
|
Sale | 593 | Mar 02, 2023 | March 3, 2023, 5:51 p.m. |
|
DGX
|
Sale | 1,415 | Feb 24, 2023 | Feb. 27, 2023, 5:49 p.m. |
|
DGX
|
Sale | 50,604 | May 17, 2022 | May 19, 2022, 4:40 p.m. |
|
DGX
|
Sale | 6,228 | Mar 08, 2022 | March 9, 2022, 5:50 p.m. |
|
DGX
|
Sale | 1,669 | Feb 24, 2022 | Feb. 28, 2022, 8:35 p.m. |
$DGX Executives and Stock Owners with Insider Trades
-
Michael E Prevoznik, SVP & General Counsel
-
Stephen H Rusckowski, Chairman, CEO and President
-
J. E. Davis, CEO and President
-
Catherine T. Doherty, EVP, Regional Businesses
-
Patrick Plewman, SVP for Diagnostic Services
-
Catherine T. Doherty, SVP, Group Exec. Clin. Fran.
-
Karthik Kuppusamy, SVP, Clinical Solutions
-
Michael J Deppe, SVP, Corp. Controller & CAO
-
Catherine T. Doherty, SVP, Regional Businesses
-
Mark E Delaney, SVP & Chief Commercial Officer
-
Michael J Deppe, VP, Corp. Controller & CAO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.